Smith Group Asset Management’s ANI Pharmaceuticals ANIP Stock Holding History

Smith Group Asset Management’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-2,180	Closed	-$134K	–	359
2019 Q4	$134K	Hold	2,180	–	–	0.01%	228
2019 Q3	$159K	Sell	2,180 -3,480	-61%	-$260K	0.01%	208
2019 Q2	$465K	Hold	5,660	–	–	0.02%	161
2019 Q1	$399K	Sell	5,660 -11,530	-67%	-$678K	0.01%	182
2018 Q4	$774K	Sell	17,190 -6,770	-28%	-$355K	0.03%	175
2018 Q3	$1.35M	Buy	23,960 +4,140	+21%	+$253K	0.04%	153
2018 Q2	$1.32M	Buy	19,820 +2,710	+16%	+$169K	0.04%	153
2018 Q1	$996K	Buy	+17,110	New	+$1.09M	0.03%	167
2016 Q4	–	Sell	-59,690	Closed	-$3.96M	–	451
2016 Q3	$3.96M	Sell	59,690 -30	-0.1%	-$1.88K	0.12%	100
2016 Q2	$3.33M	Buy	+59,720	New	+$2.9M	0.1%	105
2014 Q3	–	Sell	-1,020	Closed	-$35K	–	407
2014 Q2	$35K	Hold	1,020	–	–	﹤0.01%	287
2014 Q1	$32K	Buy	+1,020	New	+$27.1K	﹤0.01%	281

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ICOM

Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Smith Group Asset Management's ANIP Position: Q1 2020 in Review

Smith Group Asset Management sold out of ANI Pharmaceuticals (ANIP) in Q1 2020, closing a stake of 2,180 shares — an estimated $134K sold.

Smith Group Asset Management first reported a position in ANIP in Q1 2014 and held it in 12 quarters. The position peaked at $3.96M in Q3 2016. 140 funds tracked by Wall St. Rank hold ANIP as of Q1 2020.

Smith Group Asset Management reported no remaining ANI Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Smith Group Asset Management sold 2,180 ANI Pharmaceuticals shares in Q1 2020, an estimated $134K.
Smith Group Asset Management first reported a position in ANI Pharmaceuticals in Q1 2014 and held it in 12 quarters.
Smith Group Asset Management's ANI Pharmaceuticals position peaked at $3.96M in Q3 2016.
140 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2020.

Based on Smith Group Asset Management's 13F filing for Q1 2020, filed 12 May 2020.